2342 Protein production as an early pharmacodynamics biomarker for RNA-targeting therapies

Por Self, Wade K., Schoch, Kathleen, Bollinger, James, Cole, Tracy, Kordasiewicz, Holly, Bateman, Randall, Miller, Timothy
Publicado no J Clin Transl Sci (2018)

Protein production is an early biomarker for RNA‐targeted therapies

Por Self, Wade K., Schoch, Kathleen M., Alex, Jacob, Barthélemy, Nicolas, Bollinger, James G., Sato, Chihiro, Cole, Tracy, Kordasiewicz, Holly B., Swayze, Eric, Bateman, Randall J., Miller, Timothy M.
Publicado no Ann Clin Transl Neurol (2018)

In vivo kinetic approach reveals slow SOD1 turnover in the CNS

Por Crisp, Matthew J., Mawuenyega, Kwasi G., Patterson, Bruce W., Reddy, Naveen C., Chott, Robert, Self, Wade K., Weihl, Conrad C., Jockel-Balsarotti, Jennifer, Varadhachary, Arun S., Bucelli, Robert C., Yarasheski, Kevin E., Bateman, Randall J., Miller, Timothy M.
Publicado no J Clin Invest (2015)

Defining SOD1 ALS natural history to guide therapeutic clinical trial design

Por Bali, Taha, Self, Wade, Liu, Jingxia, Siddique, Teepu, Wang, Leo H, Bird, Thomas D, Ratti, Elena, Atassi, Nazem, Boylan, Kevin B, Glass, Jonathan D, Maragakis, Nicholas J, Caress, James B, McCluskey, Leo F, Appel, Stanley H, Wymer, James P, Gibson, Summer, Zinman, Lorne, Mozaffar, Tahseen, Callaghan, Brian, McVey, April L, Jockel-Balsarotti, Jennifer, Allred, Peggy, Fisher, Elena R, Lopate, Glenn, Pestronk, Alan, Cudkowicz, Merit E, Miller, Timothy M
Publicado no J Neurol Neurosurg Psychiatry (2016)